US Bio CEO Sells Millions in Stock Under Pre-Established 10b5-1 Plan

Martin Rothblatt, chairman and CEO of United Therapeutics Corporation (Nasdaq: UTHR), exercised 9,500 stock options on each of June 2, 5 and 8, 2026, at an exercise price of $146.03 per share, and then sold the same number of shares on the open market at prices ranging from approximately $536 to $551 per share.

Each transaction generated proceeds of about $5 million, totaling roughly $15 million (approximately KRW 20 billion), all executed under a prearranged Rule 10b5-1 trading plan adopted in November 2025, the company disclosed.

After these sales, CEO Rothblatt directly holds 40,513 shares, valued at about $22 million (approximately KRW 30 billion) as of the disclosure date. He also retains a significant indirect interest through a spouse and family trust.

On June 29, the company received U.S. Food and Drug Administration approval for its LungFX device for lung transplantation, a regulatory milestone that supports the expansion of its lung organ transplant platform business.

Earlier, alongside its first-quarter financial results, United Therapeutics announced a shareholder return program including up to $2 billion in share repurchases over one year and a $1.5 billion accelerated repurchase program.

United Therapeutics is a U.S. biotech and pharmaceutical firm developing treatments for rare and serious diseases such as pulmonary arterial hypertension, as well as organ replacement technologies. The company is notable for its public-benefit corporation structure.

Founder and CEO Martin Rothblatt has focused on investing in rare disease therapeutics and bioengineered organ transplant platforms. The company’s long-term option awards and related planned sales are regularly disclosed.